drugset / Trial / NCT04110093
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is intended to evaluate efficacy and safety of the combination of regorafenib and nivolumab as third-line or later therapy in patients with microsatellite stable (MSS) colorectal cancer (CRC).
Timeline
- Start
- 2019-03-01
- Primary completion
- 2021-08-31
- Completion
- 2021-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carelizumab | Unknown | 200 mg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Regorafenib | Small molecule | 80 mg | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |